Results 61 to 70 of about 26,095 (148)

Mandibular mass as the primary manifestation of multiple myeloma. [PDF]

Braz J Otorhinolaryngol, 2014
Pushpanshu K, Punyani S, Kaushik R.
europepmc   +1 more source

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. [PDF]

Haematologica, 2023
Mangiacavalli S, Cartia CS, Galli M, Pezzatti S, Belotti A, Fazio F, Mina R, Marcatti M, Cafro A, Zambello R, Paris L, Barilà G, Olivares C, Pompa A, Mazza R, Farina F, Soldarini M, Benvenuti P, Pagani G, Palumbo M, Masoni V, Ferretti VV, Klersy C, Arcaini L, Petrucci MT.   +24 more
europepmc   +1 more source

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study. [PDF]

Sao Paulo Med J, 2016
Kerbauy LN, Parmar S, Kutner JM, Gusmão BM, Hamerschlak N.   +4 more
europepmc   +1 more source

Hip Hemiarthroplasty in Patients with Multiple Myeloma: A Retrospective Case Series and Review of the Literature. [PDF]

Rev Bras Ortop (Sao Paulo)
Mahmoud AN, Ordas-Bayon A, Doyle CM, Echeverry-Martinez MF, Horwitz DS.   +4 more
europepmc   +1 more source

Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma. [PDF]

Rev Bras Enferm
Lorca LA, Sacomori C, Peña C, Barrera C, Salazar M, Leão I, Valladares X, Rojas C.   +7 more
europepmc   +1 more source

Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma. [PDF]

An Bras Dermatol, 2013
Lavorato FG, Alves Mde F, Maceira JM, Unterstell N, Serpa LA, Azulay-Abulafia L.   +5 more
europepmc   +1 more source

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. [PDF]

Cancers (Basel), 2023
Mingrone G, Astarita A, Colomba A, Catarinella C, Cesareo M, Airale L, Paladino A, Leone D, Vallelonga F, Bringhen S, Gay F, Veglio F, Milan A.   +12 more
europepmc   +1 more source

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology. [PDF]

Ann Hematol
Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F.   +43 more
europepmc   +1 more source